Summary
Eli Lilly and Company reported flat revenue of $5.60 billion for the first quarter of 2013 compared to the prior year, with net income significantly increasing by 53% to $1.55 billion, translating to diluted earnings per share (EPS) of $1.42, up from $0.91 in Q1 2012. This substantial profit increase was largely driven by a one-time income of $495.4 million recognized from the transfer of exenatide commercial rights outside the U.S. to Amylin Pharmaceuticals. Despite the strong net income growth, the company faces significant headwinds from patent expirations, notably for Zyprexa, which caused substantial sales declines, and upcoming patent cliffs for Cymbalta and Evista. Lilly is actively managing these challenges by focusing on growth in patent-protected products, emerging markets, and its animal health business. The company maintained its full-year EPS guidance of $4.10 to $4.25 and revenue forecast of $22.6 billion to $23.4 billion, indicating confidence in its strategic initiatives and product pipeline.
Financial Highlights
52 data points| Revenue | $5.60B |
| Cost of Revenue | $1.16B |
| Gross Profit | $4.44B |
| R&D Expenses | $1.35B |
| SG&A Expenses | $1.65B |
| Operating Expenses | $3.00B |
| Interest Expense | $40.30M |
| Net Income | $1.55B |
| EPS (Basic) | $1.42 |
| EPS (Diluted) | $1.42 |
| Shares Outstanding (Basic) | 1.09B |
| Shares Outstanding (Diluted) | 1.09B |
Key Highlights
- 1Revenue remained flat at $5.60 billion, but Net Income surged by 53% to $1.55 billion, driven by a $495.4 million gain from the transfer of exenatide rights.
- 2Diluted EPS increased significantly to $1.42 from $0.91 in the prior year, reflecting the impact of the exenatide rights transfer.
- 3Zyprexa sales continued to decline significantly due to patent expirations, impacting overall revenue despite growth in products like Cymbalta, Cialis, and Humalog.
- 4The company is facing upcoming patent expirations for key products like Cymbalta (US, December 2013) and Evista (US, March 2014), which are expected to materially impact future revenues.
- 5R&D expenses increased by 17% to $1.35 billion, driven by late-stage clinical trials and milestone payments related to empagliflozin and the discontinuation of the tabalumab program.
- 6Lilly completed its $1.50 billion share repurchase program in the first quarter of 2013.
- 7The company reiterated its full-year 2013 EPS guidance of $4.10-$4.25 and revenue guidance of $22.6-$23.4 billion.